The purpose of the Epithelial Keratitis Trial of the Herpetic Eye Disease Study was to evaluate the efficacy of the short-term administration of high-dose oral acyclovir, 400 mg given 5 times daily for 3 weeks, in preventing the development of HSV stromal keratitis or iritis during an episode of active HSV epithelial keratitis.1 We hypothesized that a high concentration of a systemic antiviral agent such as acyclovir provided when HSV was actively replicating in the cornea might decrease the viral and viral antigenic load in the eye and, therefore, prevent the development of stromal keratitis and iritis. However, the results of this trial showed that it did not.
Barron BA, for The Herpetic Eye Disease Study Group. Prevention of Herpes Simplex Keratitis and Iritis—Reply. Arch Ophthalmol. 1998;116(2):259. doi: